Targeting egln1 in cancer
AssigneesThe Broad Institute, Inc., Dana-Farber Cancer Institute, Inc., Instituto Carlos Slim De La Salud, A.C.
InventorsWilliam Hahn, Francisca Vazquez, Colles Price
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to compositions and methods for the diagnosis and treatment or prevention of EGLN1-dependent cancers. In particular, the instant disclosure provides for identification of a cancer as EGLN1-dependent, and selection and/or administration of an inhibitor of EGLN1 or VHL (Von Hippel-Lindau Tumor Suppressor) as a therapeutic agent for such a cancer and/or subject having or at risk of developing such a cancer.
Claims22
A method for selecting a treatment for a subject having or at risk of developing a cancer that exhibits EGLN1 dependency, the method comprising:
- (a) obtaining a sample from a subject having or at risk of developing a cancer that exhibits EGLN1 dependency;
- (b) identifying the presence or absence in the sample of EGLN1 dependency;
- and
- (c) selecting an EGLN1 inhibitor or a VHL inhibitor as a treatment for the subject if EGLN1 dependency is identified in the sample, thereby selecting a treatment for the subject having or at risk of developing a cancer that exhibits EGLN1 dependency.
A composition selected from the group consisting of:
- A kit for identifying EGLN1 dependency in a sample and selecting an EGLN1 inhibitor or a VHL inhibitor therapy for a subject, and instructions for its use;
- and
- A pharmaceutical composition for treating a subject having an EGLN1-dependent cancer comprising a therapeutically effective amount of an EGLN1 inhibitor or a VHL inhibitor and a pharmaceutically acceptable carrier.
A method for treating or preventing a melanoma or an ovarian cancer in a subject having or at risk of developing such a cancer, comprising:
- (a) obtaining a sample from a subject having or at risk of developing a melanoma or an ovarian cancer;
- (b) identifying the presence or absence in the sample of EGLN1 dependency;
- and
- (c) administering an EGLN1 inhibitor or a VHL inhibitor to the subject if EGLN1 dependency is identified in the sample, thereby treating or preventing a melanoma or an ovarian cancer in a subject having or at risk of developing such a cancer.
19-21. (canceled)
24-25. (canceled)
Dependencies are inferred from the claim text.